Crispr Theraptc (NASDAQ:CRSP)‘s stock had its “hold” rating reaffirmed by stock analysts at Cann in a report issued on Thursday.
The analysts wrote, “Loss per share was $0.62, compared to our estimated loss per share of $0.51. This was the result of higher than expected SG&A of $8.1 million, compared to our estimate of $6.5 million; as well as a loss from equity method investment of $0.4 million compared to our estimate of $0.0 million. The higher-than-anticipated SG&A expenses are due to a slightly earlier-than-anticipated administrative ramp, which we anticipated would occur in the fourth quarter. As a result, we are not changing our estimates for full year estimated 2017 SG&A expenses. There were no other meaningful variances in the quarter.””
CRSP has been the topic of several other reports. Barclays PLC reiterated a “buy” rating and issued a $29.00 target price on shares of Crispr Theraptc in a report on Friday, September 8th. Chardan Capital reiterated a “buy” rating on shares of Crispr Theraptc in a report on Monday, August 14th. SunTrust Banks, Inc. began coverage on Crispr Theraptc in a report on Thursday, July 13th. They issued a “hold” rating and a $16.00 target price on the stock. Finally, Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Crispr Theraptc in a report on Tuesday, July 18th. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Crispr Theraptc has a consensus rating of “Buy” and a consensus price target of $23.08.
Crispr Theraptc (NASDAQ CRSP) traded up $0.50 during trading on Thursday, hitting $17.45. The stock had a trading volume of 123,300 shares, compared to its average volume of 129,832. Crispr Theraptc has a one year low of $11.63 and a one year high of $25.00.
Crispr Theraptc (NASDAQ:CRSP) last released its quarterly earnings data on Wednesday, November 8th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($0.02). Crispr Theraptc had a negative net margin of 466.58% and a negative return on equity of 38.42%. The firm had revenue of $2.39 million during the quarter, compared to analyst estimates of $3.61 million. During the same period in the prior year, the company earned ($2.77) EPS. The business’s quarterly revenue was up 54.2% compared to the same quarter last year. analysts expect that Crispr Theraptc will post -2.46 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Crispr Theraptc (CRSP) Rating Reiterated by Cann” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2017/11/11/crispr-theraptc-crsp-rating-reiterated-by-cann.html.
In related news, Director Kurt Von Emster sold 3,150 shares of the stock in a transaction on Monday, August 21st. The stock was sold at an average price of $18.52, for a total value of $58,338.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Samarth Kulkarni sold 27,154 shares of the stock in a transaction on Wednesday, August 30th. The shares were sold at an average price of $20.08, for a total value of $545,252.32. Following the completion of the sale, the insider now directly owns 110,893 shares of the company’s stock, valued at $2,226,731.44. The disclosure for this sale can be found here. Over the last quarter, insiders sold 343,060 shares of company stock worth $6,778,681. 39.98% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CRSP. Credit Suisse AG purchased a new stake in Crispr Theraptc in the 1st quarter valued at $1,742,000. Wells Fargo & Company MN increased its position in shares of Crispr Theraptc by 459.7% during the 2nd quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock valued at $128,000 after purchasing an additional 6,560 shares during the last quarter. Vanguard Group Inc. purchased a new stake in shares of Crispr Theraptc during the 2nd quarter valued at $273,000. Ark Investment Management LLC purchased a new stake in shares of Crispr Theraptc during the 2nd quarter valued at $206,000. Finally, Moloney Securities Asset Management LLC purchased a new stake in shares of Crispr Theraptc during the 3rd quarter valued at $235,000. 25.52% of the stock is owned by institutional investors and hedge funds.
About Crispr Theraptc
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Ratings for Crispr Theraptc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Theraptc and related companies with MarketBeat.com's FREE daily email newsletter.